Uncommon phenotypes of acute myelogenous leukemia: Basophilic, mast cell, eosinophilic, and myeloid dendritic cell subtypes: A review

被引:17
作者
Lichtman, MA [1 ]
Segel, GB
机构
[1] Univ Rochester, Med Ctr, Dept Med Hematol Oncol, Rochester, NY 14642 USA
[2] Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA
[3] Univ Rochester, Med Ctr, Dept Pediat Hematol Oncol Genet, Rochester, NY 14642 USA
[4] Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14642 USA
关键词
myelogenous leukemia; basophilic leukemia; mast cell leukemia; eosinophilic leukemia; dendritic cell leukemia; clonal myeloid diseases; leukemia classification;
D O I
10.1016/j.bcmd.2005.08.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The potential of the transformed (leukemic) multipotential hematopoietic cell to differentiate and mature along any myeloid lineage forms the basis for the phenotypic classification of acute and chronic myelogenous leukemia. Although most cases of leukemia can be classified phenotypically by the dominant lineage expressed, the genotype within each phenotype is heterogeneous. Thus, covert genetic factors, cryptic mutations, and/or polymorphisms may interact with the seminal transforming genetic mutations to determine phenotype. The phenotype usually is expressed sufficiently to determine the lineage that is dominant in the leukemic clone by light microscopic examination, by cytochemistry of blood and marrow cells, and by immunophenotyping. The basis for the frequency of the AML phenotypes is unclear, although there is a rough concordance with the frequency of marrow precursor cells of different lineages. The least common AML phenotypes are a reflection of the least common blood or marrow cell lineages: acute basophilic, acute mast cell, acute eosinophilic, and acute myeloid dendritic cell leukemia. We discuss the features of these uncommon phenotypes and review the criteria used for their diagnosis. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:370 / 383
页数:14
相关论文
共 111 条
[1]   A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib [J].
Akin, C ;
Fumo, G ;
Yavuz, AS ;
Lipsky, PE ;
Neckers, L ;
Metcalfe, DD .
BLOOD, 2004, 103 (08) :3222-3225
[2]   An unusual case of CD4+CD7+CD56+acute leukemia with overlapping features of type 2 dendritic cell (DC2) and myeloid/NK cell precursor acute leukemia [J].
Anargyrou, K ;
Paterakis, G ;
Boutsis, D ;
Politou, M ;
Papadhimitriou, SI ;
Siakandaris, M ;
Vassiliadis, J ;
Androulakis, A ;
Meletis, J ;
Rombos, J ;
Tassiopoulou, A ;
Vaiopoulos, G .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2003, 71 (04) :294-298
[3]  
[Anonymous], 2001, WHO CLASSIFICATION T
[4]  
ANTEUNIS A, 1978, VIRCHOWS ARCH B, V27, P237
[5]  
Anteunis A, 1977, Inflammation, V2, P17, DOI 10.1007/BF00920871
[6]  
Arock M, 2002, J LEUKOCYTE BIOL, V71, P557
[7]  
ATTILIO G, 1986, AM J HEMATOL, V21, P29
[8]  
Baghestanian M, 1996, LEUKEMIA, V10, P159
[9]   Core-binding factor-β positive acute myeloid leukaemia cells induce T-cell responses [J].
Banat, GA ;
Ihlow, K ;
Usluoglu, N ;
Hoppmann, S ;
Hoeck, M ;
Pralle, H .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 123 (05) :819-829
[10]   Plasmacytoid dendritic cells:: From the plasmacytoid T-cell to type 2 dendritic cells CD4+CD56+ malignancies [J].
Béné, MC ;
Feulliard, J ;
Jacob, MC .
SEMINARS IN HEMATOLOGY, 2003, 40 (03) :257-266